Tony Gibney is a Managing Director at Leerink Swann in New York, where he has led the Firm’s East Coast biopharmaceuticals investment banking franchise since joining the firm in mid-2009. In addition to having primary coverage responsibilities for East Coast biopharma companies, Tony also manages several relationships with larger European-based pharmaceutical companies. Prior to joining Leerink, Tony led the East Coast biotechnology and branded specialty pharmaceutical effort for the majority of his 10-year tenure at Merrill Lynch. In all, over 15 former Merrill Lynch investment bankers have been a part of Leerink’s investment banking group since 2009. Prior to Merrill, Tony was an analyst and associate in the Healthcare Investment Banking Group at Lehman Brothers from 1993 to 1999.
Tony has executed over 100 M&A transactions, book-run financings and other structured transactions over his 19-year, life sciences-focused investment banking career. Successfully concluded transactions have included private placements, initial public offerings, add-on offerings, convertible offerings and royalty transactions, as well as sell-side, buy-side and structured collaboration strategic advisory assignments for life science clients.
At Leerink Swann, Tony has helped to combine the Firm’s MedaCorp, consulting and other unique knowledge resources with the senior execution experience to upgrade the Firm’s leadership roles in financings and M&A for larger, more visible biopharmaceutical clients. In such transactions, the Firm often collaborates with bulge bracket peers, whose resources generally complement Leerink’s capabilities, to improve transactional success. Tony has executed transactions for over 20 biopharmaceutical companies while at Leerink, including multiple deals for several clients.
Tony graduated with distinction from Yale University in 1993 a B.A. in history and economics.